Novartis Pushes Dermatology Momentum By Licensing Atopic Dermatitis MAb

Novartis is hoping to use its considerable Cosentyx sales slipstream and internal dermatology engine to develop its next skin success by licensing-in a novel antibody against IL-17C from Galapagos and MorphoSys.

Cycling
Novartis pushes ahead with dermatology

Novartis AG is hammering home its commitment to immune-dermatology by in-licensing MOR106, a novel antibody against IL-17C indicated in atopic dermatitis (AtD), from biotechs Galapagos NV and MorphoSys AG for €95m ($111m) upfront, which the companies will split 50/50.

The Swiss pharma's key new product, Cosentyx (secukinumab) an antibody targeting IL-17A for psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip